Production of an active Mus musculus IL-3 using updated silkworm-based baculovirus expression vector system

• Published in: Journal of Asia-Pacific entomology 2021, 24(3), , pp.544-549
• Main Authors: Nagai, Ryo, Ebihara, Takeru, Kakino, Kohei, Masuda, Akitsu, Xu, Jian, Minamihata, Kosuke, Kamiya, Noriho, Kongkrongtong, Tatphon, Kawahara, Masahiro, Mon, Hiroaki, Fujii, Tsuguru, Kusakabe, Takahiro, Lee, Jae Man
• Format: Article
• Language: English
• Subjects: Baculovirus; Interleukin; Mouse IL-3; Silkworm expression system; 농학
• ISSN: 1226-8615; 1876-7990
• DOI: 10.1016/j.aspen.2021.04.011

[Display omitted] •• Recombinant MmIL-3 was purified from the silkworm-BEVS.•• Silkworm-derived rMmIL-3 was N-glycosylated.•• Active rMmIL-3 has been verified in Ba/F3 cells. Due to the biological significance and therapeutic potential of Interleukin-3 (IL-3) secreted mainly by activated T cells, various protein expression systems have been challenged to produce recombinant IL3 to meet the increasing demands worldwide. Recently, we established an updated silkworm-based baculovirus expression vector system (silkworm-BEVS), which in most cases, produces eukaryotic proteins in biological or enzymatical active forms with considerable amounts. We attempted to reconstruct and express a recombinant mouse IL-3 (rMmIL-3) with C-terminal His8-Strep tags in silkworm-BEVS in the current study. From our results, we gained an active glycosylated rMmIL-3 protein in a substantial amount and quality. As compared with the E. coli expression system, silkworm-BEVS is a better choice regarding the glycosylations attached in rMmIL-3 and up-scalable system in case that a commercial amount is required in the future. Collectively, our method shares an excellent model to produce interleukin molecular for approaching pharmaceutical applications.